Effect of the Multi-Strain Probiotic SYN-53 in the Management of Allergic Rhinoconjunctivitis.

Allergy · 2025 · PMC12368763 · PMID 40577168

Europe PMC DOI

hedged sentence

0.0067

closest p · 0.1× alpha

0.0067

boldest claim

The sentences

showed a trendp = 0.0067actually significant

After one intake cycle, SYN‐53 already showed a trend towards greater efficacy over placebo, which became significant after two cycles (ΔTSS MAX : −3.44 ± 0.42 vs. −1.87 ± 0.37; p = 0.0067), with 38% vs. 24% symptom relief.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.